Effect of St. John’s wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers

References

• Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I. (2003). Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John’s wort in renal transplant patients. Br J Clin Pharmacol 55:203–11.
   PubMed Web of Science ®Google Scholar
• Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. (2000a). Drug interaction of St. John’s wort with cyclosporin. Lancet 355:1912.
   PubMed Web of Science ®Google Scholar
• Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. (2000b). Profound drop of cyclosporin A whole blood trough levels caused by St. John’s wort (Hypericum perforatum).Transplantation 69:2229–30.
   PubMed Web of Science ®Google Scholar
• Butterweck V, Schmidt M. (2007). St. John’s wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 157:356–61.
   PubMedGoogle Scholar
• Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–30.
   PubMed Web of Science ®Google Scholar
• Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. (2001). Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123–9.
   PubMed Web of Science ®Google Scholar
• Foley KF, DeSanty KP, Kast RE. (2006). Bupropion: pharmacology and therapeutic applications. Exp Rev Neurotherapeut 6:1249–65.
   PubMed Web of Science ®Google Scholar
• Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. (2004). Effect of St. John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323–9.
   PubMed Web of Science ®Google Scholar
• Fugh-Berman A, Ernst E. (2001). Herb–drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52:587–95.
   PubMed Web of Science ®Google Scholar
• Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. (2001). Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60:427–31.
   PubMed Web of Science ®Google Scholar
• Greeson JM, Sanford B, Monti DA. (2001). St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology(Berl) 153:402–14.
   PubMed Web of Science ®Google Scholar
• Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. (2003). The interaction between St. John’s wort and an oral contraceptive. Clin Pharmacol Ther 74:525–35.
   PubMed Web of Science ®Google Scholar
• Haynes KFS, Lindley C, LeCluyse E, Shord S, Hawke R. (2002). Evaluation of buproprion hydroxylation as a probe for cytochrome P450 2B6 activity in cultured human hepatocytes. Poster presented at the American College of Clinical Pharmacy Savannah, GA, USA, 10 April 2002.
   Google Scholar
• Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. (2002). St. John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349–56.
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176–83.
   PubMed Web of Science ®Google Scholar
• Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM. (2007) Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 81:69–75.
   PubMed Web of Science ®Google Scholar
• Holm KJ, Spencer CM. (2000). Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007–24.
   PubMed Web of Science ®Google Scholar
• Ioannides C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451–78.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Ernst E. (2001). Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61:2163–75.
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Pradko JF, Muir KT. (2005). Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 27:1685–95.
   PubMed Web of Science ®Google Scholar
• Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, Scholler G., Langheinrich M, Roots I. (2002). Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol 22:46–54.
   PubMed Web of Science ®Google Scholar
• Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ. (2006). Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 80:75–84.
   PubMed Web of Science ®Google Scholar
• Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. (2003). Impact of St. John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18:819–22.
   PubMed Web of Science ®Google Scholar
• Mueller SC, Majcher-Peszynska J, Mundkowski RG. (2009). No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 65:81–7.
   PubMed Web of Science ®Google Scholar
• Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. (2006). The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 62:29–36.
   PubMed Web of Science ®Google Scholar
• Murphy PA. (2002). St. John’s wort and oral contraceptives: reasons for concern? J Midwife Women Hlth 47:447–50.
   PubMedGoogle Scholar
• Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. (2003). Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 74:326–33.
   PubMed Web of Science ®Google Scholar
• Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. (2005). Opposite effects of short-term and long-term St. John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78:25–33.
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. (2007). Induction of intestinal P-glycoprotein by St. John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669–78.
   PubMed Web of Science ®Google Scholar
• Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. (2004). St. John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 75:298–309.
   PubMed Web of Science ®Google Scholar
• Timbo BB, Ross MP, McCarthy PV, Lin CT. (2006). Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc 106:1966–74.
   PubMed Web of Science ®Google Scholar
• Ute Gödtel–Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. (2007). Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John’s wort. Naunyn-Schmiedeberg’s Arch Pharmacol 375:377–82.
   Google Scholar
• Williams JW Jr, Holsinger T. (2005). St. John’s for depression, worts and all. Br Med J 330:E350–1.
   Google Scholar
• Wurglics M, Westerhoff K, Holoubek G, Schubert-Zsilavecz M, Mueller W. (2002). Aktuelle Johanniskrautforschung. Deutsche Apothekerzeitung 142:1153–75.
   Google Scholar
• Xie HG, Kim RB. (2005). St. John’s wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 78:19–24.
   PubMed Web of Science ®Google Scholar
• Zanoli P. (2004). Role of hyperforin in the pharmacological activities of St. John’s wort. CNS Drug Rev 10:203–18.
   PubMedGoogle Scholar